Due Diligence: Calculating the Regulatory Review Period for Patent Term Extension

by Pepper Hamilton LLP
Contact

Pepper Hamilton LLP

This is the fourth article in our five-part series on PTE.

When applying for a patent term extension (PTE), due diligence matters. If an applicant did not act with due diligence during the testing phase or the approval phase, the time during which it failed to do so will be deducted from the PTE.1 But there has been little guidance on what constitutes due diligence or on the use of due diligence petitions to challenge PTE determinations. Because due diligence is critical in PTE decisions:

  • Applicants should consult with patent and regulatory counsel to ensure that the due diligence standard has been met.

In the context of the regulatory review period used to calculate a PTE award, “due diligence” is defined as the degree of attention, continuous directed effort, and timeliness that may reasonably be expected from, and are ordinarily exercised by, a person during a regulatory review period.2 FDA considers all relevant factors, including the amount of time between approval of the investigational exemption and the start of a clinical trial and the amount of time required to conduct a clinical trial.3 Other factors may include:

  1. The length of regulatory review periods for comparable products, where appropriate
  2. Compliance or failure to comply with FDA requirements, including prescribed laws and regulations
  3. Time solely attributable to FDA action as part of its regulatory review of the marketing application
  4. Independent action by federal, state or local governments that interrupts testing, submission of data or other required activities
  5. Unavailability of any key person involved in the applicant’s activities during regulatory review
  6. Physical destruction of essential testing facilities or essential data
  7. Delay caused by financial considerations
  8. Implementation or failure to implement ordinary and necessary measures to minimize delay.4

FDA ultimately determines the regulatory review period and publishes its initial finding in the Federal Register. Within 180 days of publication, any person may challenge the determination by alleging that the applicant for PTE did not act with due diligence in seeking FDA approval of the product during the regulatory review period.5 The “due diligence petition” must claim that the applicant did not act with due diligence during some part of the regulatory review period and must include sufficient facts to merit an FDA investigation into the applicant’s due diligence.6

Within 90 days of receiving the petition, FDA will either deny the petition or investigate to determine whether the applicant acted with due diligence. It will then publish its determination in the Federal Register.7 If any person is not satisfied with FDA’s due diligence determination, he or she may request, no later than 60 days after the determination was published, that FDA conduct an informal hearing on the due diligence determination.8 The requesting party, the petitioner (if different) and the applicant all may participate in the hearing, but the requesting party bears the burden of proof.9

To date, it appears that only four due diligence petitions have even been filed, and only one was actually decided by FDA. The four petitions are (1) the Sapien Transcatheter Heart Valve (2012; withdrawn), (2) Mifeprex® (2002; rendered moot), (3) Nexium® (2001; withdrawn), and (4) Lopressor® OROS® (1991; denied). A description of each is below:

  • The law firm Sterne Kessler Goldstein & Fox challenged Edwards Lifesciences AG’s PTE application for its heart valve device, the Sapien Transcatheter Heart Valve. It alleged that Edwards unreasonably delayed FDA approval of the Sapien device in three ways: (1) suspending or delaying its clinical trials; (2) making major design modifications that were unnecessary and unduly delayed marketing approval; and (3) requesting at least 15 separate time extensions to provide additional information to FDA, all related to the design change. Sterne withdrew its petition before FDA could review it, and Edwards eventually received a 1,420-day PTE.
  • Corcept Therapeutics Inc. filed a due diligence petition alleging that the Population Council did not act with due diligence during the regulatory review period of Mifeprex (mifepristone). Corcept contended that the applicant unreasonably delayed FDA approval for more than four years because it could not secure an adequate manufacturing source between the initial 1996 approvable letter and its final approval in 2000. FDA rendered the due diligence petition moot in light of its decision to reduce the regulatory review period under Corcept’s request for revision of the period.
  • Dr. Reddy’s claimed that AstraZeneca did not act with due diligence during the regulatory review period of Nexium (esomeprazole). In response, AstraZeneca said that FDA should dismiss the petition because it raised an issue of eligibility for PTE, not a failure to act with due diligence. Dr. Reddy’s withdrew the petition before any FDA ruling.
  • Ciba-Geigy Corp. alleged that Aktiebolaget Hassle did not act with due diligence during the regulatory review period of Lopressor OROS. Ciba-Geigy contended that the applicant, Hassle, was not entitled to seek PTE because there was no agency relationship between the two parties with respect to Lopressor OROS. In other words, Hassle could not have acted with due diligence because neither it nor its agent played any role in the development of Lopressor OROS. FDA denied the petition, stating that it failed to allege laxity in the pursuit of marketing approval, which is under the auspices of FDA. Rather, the petition alleged that Hassle was not entitled to obtain PTE, which is under the auspices of the USPTO.

Innovators should consult with both patent and regulatory counsel to ensure that the innovator is acting with the necessary due diligence during both the testing and approval phases for their products, and they should explore ways to address possible delays in development with the least likely impact on PTE awards.

 

 

 

Endnotes

1 See 35 U.S.C. § 156(c)(1).

2 See 35 U.S.C. § 156(d)(3).

3 See 21 C.F.R. § 60.36(a).

4 See Proposed Patent Term Restoration Regulations, Proposed Rule, 51 Fed. Reg. 25338 (July 11, 1986). These eight additional factors were part of the original proposed rule, but they were ultimately excluded by FDA from the final rule. In promulgating the final rule, FDA emphasized that “these types of events are not exhaustive but rather are intended only to provide potential due diligence petitioners with some idea of the types of events FDA will consider in its due diligence determinations.” 53 Fed. Reg. 7289 (Mar. 7, 1988).

5 See 21 C.F.R. § 60.30(a).

6 See 21 C.F.R. § 60.30(c)-(d).

7 See 21 C.F.R. § 60.34(a).

8 See 21 C.F.R. § 60.40.

9 See 21 C.F.R. §§ 60.42, 60.44, 60.46.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Written by:

Pepper Hamilton LLP
Contact
more
less

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.